Safinamide, a New Anti-Parkinson Agent, is Effective and well-tolerated in Early Parkinson’s Disease PD Patients on a Stable Dose of a Single DA-Agonist: Results of a Randomized, International, Placebo-controlled, Phase III Trial Read more about Safinamide, a New Anti-Parkinson Agent, is Effective and well-tolerated in Early Parkinson’s Disease PD Patients on a Stable Dose of a Single DA-Agonist: Results of a Randomized, International, Placebo-controlled, Phase III Trial
Safinamide - Abstracts from Movement Disorder Society's 11th International Congress, Istanbul Read more about Safinamide - Abstracts from Movement Disorder Society's 11th International Congress, Istanbul
